---
title: "Joinn Laboratories (China) Co., Ltd. (603127.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/603127.SH.md"
symbol: "603127.SH"
name: "Joinn Laboratories (China) Co., Ltd."
industry: "Life Sciences Tools and Services"
datetime: "2026-04-30T23:18:11.872Z"
locales:
  - [en](https://longbridge.com/en/quote/603127.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/603127.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/603127.SH.md)
---

# Joinn Laboratories (China) Co., Ltd. (603127.SH)

## Company Overview

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People’s Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | CN Market |
| Website | [www.joinnlabs.com](https://www.joinnlabs.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-30T04:30:12.000Z

**Overall: C (0.52)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 16 / 25 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -17.87% |  |
| Net Profit YoY | 302.08% |  |
| P/B Ratio | 3.38 |  |
| Dividend Ratio | 0.08% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 28957779559.68 |  |
| Revenue | 1657794006.42 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.63% | C |
| Profit Margin | 17.97% | A |
| Gross Margin | 16.98% | D |
| Revenue YoY | -17.87% | E |
| Net Profit YoY | 302.08% | A |
| Total Assets YoY | 3.04% | C |
| Net Assets YoY | 3.05% | C |
| Cash Flow Margin | 149.26% | B |
| OCF YoY | -17.87% | E |
| Turnover | 0.17 | D |
| Gearing Ratio | 14.01% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Joinn Laboratories (China) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-17.87%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "302.08%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.38",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.08%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "28957779559.68",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1657794006.42",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.63%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "17.97%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "16.98%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "-17.87%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "302.08%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "3.04%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.05%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "149.26%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-17.87%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.01%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 58.83 | 10/25 | 116.57 | 91.43 | 49.93 |
| PB | 3.40 | 14/25 | 3.39 | 3.05 | 2.39 |
| PS (TTM) | 17.27 | 24/25 | 16.55 | 13.87 | 9.77 |
| Dividend Yield | 0.08% | 19/25 | 0.63% | 0.09% | 0.08% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | WuXi AppTec (603259.SH) | A | A | C | A | B | B |
| 02 | Pharmaron (300759.SZ) | B | B | C | C | B | B |
| 03 | Tigermed (300347.SZ) | C | B | D | A | B | B |
| 04 | Chemexpress (688131.SH) | B | B | C | C | B | B |
| 05 | HitGen (688222.SH) | B | B | E | A | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-28T16:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 43% |
| Overweight | 1 | 14% |
| Hold | 2 | 29% |
| Underweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 38.87 |
| Highest Target | 45.83 |
| Lowest Target | 12.60 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/603127.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/603127.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/603127.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/603127.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**